Relapse after withdrawal from anti‐TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta‐analysis

Background Infliximab and adalimumab have established roles in inflammatory bowel disease (IBD) therapy. UK regulators mandate reassessment after 12 months' anti‐TNF therapy for IBD, with consideration of treatment withdrawal. There is a need for more data to establish the relapse rates followi...

Full description

Bibliographic Details
Main Authors:	Kennedy, NA, Warner, B, Johnston, EL, Flanders, L, Hendy, P, Ding, NS, Harris, R, Fadra, AS, Basquill, C, Lamb, CA, Cameron, FL, Murray, CD, Parkes, M, Gooding, I, Ahmad, T, Gaya, DR, Mann, S, Lindsay, JO, Gordon, J, Satsangi, J, Hart, A, McCartney, S, Irving, P, Lees, CW
Format:	Journal article
Published:	Wiley 2016

Relapse after withdrawal from anti‐TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta‐analysis

Similar Items